D
DIAMEDICA INC.
DiaMedica Therapeutics is a biopharmaceutical company that specializes in creating synthetic proteins to treat a variety of conditions.
Country/Area ：Philippines
Company Email ：info@diamedica.com
Industry ：Food and AgricultureElectronicsHealthcareBiopharmaPharmaceuticals
Company address ：Winnipeg
Company website ：*****
Company phone ：(763) 612-6755
Established ：2000-01-01
Company Revenue ：$4,726,000
Number of employees ：3
SIC Code ：28283
NAICS Code ：32325
Main Products ：DM199 for PreeclampsiaStock DataFor PhysiciansDM199 for Acute Ischemic Stroke (AIS)Literature & PublicationsStroke DiseaseFinancial Reports & SEC FilingsDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial ResultsAnalyst CoverageDiaMedica Therapeutics Upcoming Conference ParticipationAcute Ischemic StrokeDiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Company News
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
Nov 9, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023. Investors and attendees that would like to sched
Nov 9, 2023
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023Nov 6, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13th. DiaMedica will host a live conference call on Tuesday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results.
Nov 6, 2023DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerSep 12, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica’s manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resol
Sep 12, 2023DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceSep 6, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023. Management will conduct one-on-one meetings with investors during the conference. To receive additional information or to s
Sep 6, 2023DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call TranscriptAug 15, 2023
DiaMedica Therapeutics Inc. (NASDAQ:NASDAQ:DMAC) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ETCompany ParticipantsRick Pauls - President and CEOScott Kellen - CFOConference...
Aug 15, 2023Web Summary
Q1: What is the company name and its official address?
A1: The company name is DiaMedica Therapeutics, Inc. (DMAC), but the provided text does not explicitly mention the exact address of the company.
Q2: What products or therapies are being developed by DiaMedica Therapeutics?
A2: DiaMedica Therapeutics is developing a recombinant protein replacement therapy called DM199 (rhKLK1), which mimics the behavior of naturally-occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall endothelial health.
Q3: In what industry or sector is DiaMedica Therapeutics operating?
A3: DiaMedica Therapeutics is a clinical-stage biopharmaceutical company, operating in the pharmaceutical and biotechnology industry.
Q4: What are the main diseases or conditions being targeted by DiaMedica Therapeutics' products?
A4: The company's initial focus is on acute ischemic stroke (AIS) and preeclampsia (PE), with potential applications for other vascular diseases where promoting homeostasis and improving blood flow throughout the body is beneficial.
Q5: What is the mechanism of action of DiaMedica Therapeutics' lead candidate, DM199?
A5: DM199 has a unique natural mechanism of action that involves stimulating the production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factors, which work synergistically to improve blood flow and reduce inflammation.
Q6: What is the current status of DiaMedica Therapeutics' clinical trials?
A6: The company is currently conducting clinical trials for its lead candidate, DM199, as a treatment option for patients with acute ischemic stroke (AIS) and preeclampsia (PE).
Q7: Who are the key stakeholders or partners involved in DiaMedica Therapeutics' development efforts?
A7: The company collaborates with physician investigators and trial participants to demonstrate the potential of its therapies, and also works with a leadership team that draws on expertise in all stages of clinical and biopharmaceutical development.
Q8: What is the company's vision or mission statement?
A8: DiaMedica Therapeutics aims to improve patient care by developing innovative therapies that reduce ischemia and redefine what's possible for patients with severe vascular diseases.
A1: The company name is DiaMedica Therapeutics, Inc. (DMAC), but the provided text does not explicitly mention the exact address of the company.
Q2: What products or therapies are being developed by DiaMedica Therapeutics?
A2: DiaMedica Therapeutics is developing a recombinant protein replacement therapy called DM199 (rhKLK1), which mimics the behavior of naturally-occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall endothelial health.
Q3: In what industry or sector is DiaMedica Therapeutics operating?
A3: DiaMedica Therapeutics is a clinical-stage biopharmaceutical company, operating in the pharmaceutical and biotechnology industry.
Q4: What are the main diseases or conditions being targeted by DiaMedica Therapeutics' products?
A4: The company's initial focus is on acute ischemic stroke (AIS) and preeclampsia (PE), with potential applications for other vascular diseases where promoting homeostasis and improving blood flow throughout the body is beneficial.
Q5: What is the mechanism of action of DiaMedica Therapeutics' lead candidate, DM199?
A5: DM199 has a unique natural mechanism of action that involves stimulating the production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factors, which work synergistically to improve blood flow and reduce inflammation.
Q6: What is the current status of DiaMedica Therapeutics' clinical trials?
A6: The company is currently conducting clinical trials for its lead candidate, DM199, as a treatment option for patients with acute ischemic stroke (AIS) and preeclampsia (PE).
Q7: Who are the key stakeholders or partners involved in DiaMedica Therapeutics' development efforts?
A7: The company collaborates with physician investigators and trial participants to demonstrate the potential of its therapies, and also works with a leadership team that draws on expertise in all stages of clinical and biopharmaceutical development.
Q8: What is the company's vision or mission statement?
A8: DiaMedica Therapeutics aims to improve patient care by developing innovative therapies that reduce ischemia and redefine what's possible for patients with severe vascular diseases.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
